Legend Biotech: 50% of CARVYKTI Patients Progression-Free at 5 Years
LEGN sits 18% above its 52-week low of $16.24.
Summary
Legend Biotech presented five-year CARVYKTI data showing 50% of patients remained progression-free and alive after a single infusion, with 69.2% overall survival.
Key Events · Product Development and Regulatory · LEGN
-
Five-Year PFS Data
10 of 20 patients (50%) in CARTITUDE-2 Cohort A remained alive and progression-free without maintenance therapy at 5 years after a single CARVYKTI infusion.
-
Overall Survival
Five-year overall survival rate was 69.2%; median overall survival was not reached at the time of analysis.
-
Durability Signal
Median progression-free survival was 60.5 months, supporting earlier-line use of CARVYKTI in relapsed/refractory multiple myeloma.
-
Safety Update
One new acute myeloid leukemia case and two deaths (progressive disease and new cancer) occurred since the prior ~30-month analysis; no new CAR T-cell-related neurotoxicity reported.
Analysis · LEGN · Life Sciences
Five-year follow-up from CARTITUDE-2 Cohort A shows half of patients remained alive and progression-free without maintenance therapy after a single CARVYKTI infusion, with a 69.2% overall survival rate. This is the longest follow-up yet for CARVYKTI in earlier-line relapsed/refractory multiple myeloma and strengthens the case for earlier use, which could expand the addressable market. The data also note one new AML case and two deaths since the prior analysis, a safety signal worth tracking but consistent with the known secondary-malignancy risk.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LEGN was trading at $19.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $16.24 to $37.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.